Roth MKM Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Roth MKM has maintained a Buy rating for Fortress Biotech (NASDAQ:FBIO) but reduced its price target from $30.00 to $15.00. Despite the reduction, the new target suggests a significant upside from the current trading price of $1.99, with a potential increase of 653.77%. Fortress Biotech is a biopharmaceutical company with a focus on acquiring, developing, and commercializing pharmaceutical and biotechnology products, primarily in dermatology.
November 29, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM maintains a Buy rating on Fortress Biotech but lowers the price target to $15, indicating a potential 653.77% increase from the current price.
The maintenance of a Buy rating by Roth MKM suggests continued confidence in Fortress Biotech's fundamentals, while the price target reduction could reflect adjustments in market conditions or company valuation. However, the substantial potential upside indicated by the new price target may positively influence investor sentiment and drive short-term interest in the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100